Glucocorticoids are used extensively to treat autoimmune hemolytic anemias. Some beneficial effects of glucocorticoid pulse therapy have also been reported in sickle cell disease and paroxysmal nocturnal hemoglobinuria. Based on established concepts of hemoglobin (Hb) toxicity and physiologic Hb scavenger systems, we evaluated whether glucocorticoids could support an adaptive response to extracellular Hb independently of their immunosuppressive activities. Using global proteome and transcriptome analysis with mass-spectrometry (isobaric tag for relative and absolute quantitation and liquid chromatography-mass spectrometry) and gene-array experiments, we found that glucocorticoid treatment in vitro and in patients on glucocorticoid-pulse therapy polarized monocytes into a M2/alternatively activated phenotype with high Hb-scavenger receptor (CD163) expression and enhanced Hbclearance and detoxification capability. Monocytes concurrently exposed to the interactive activity of glucocorticoids and extracellular Hb were characterized by high expression of a group of antioxidant enzymes known to be regulated by the conserved oxidative response transcription factor nuclear factor E2-related factor. Further, suppressed transferrin receptor, together with high ferroportin expression, pointed to a shift in iron homeostasis directed toward an increased cellular export of heme-derived iron. Therefore, stimulating Hb-endocytosis by CD163 and enhancing antioxidative homeostasis and iron recycling may be an essential activity of glucocorticoids that helps alleviate the adverse effects of extracellular Hb. (Blood. 2010;116(24):5347-5356)
IntroductionGlucocorticoids are used extensively to treat inflammatory and autoimmune diseases. In autoimmune hemolytic anemia, glucocorticoids are thought to attenuate the production of erythrocytedirected autoantibodies while reducing destruction of immunoglobulin-coated red blood cells by macrophages within the reticuloendothelial system. 1 Intriguingly, randomized clinical trials demonstrated that glucocorticoid pulse therapy also has short-term beneficial effects on complications of nonimmune hemolysis such as acute chest syndrome and pain crisis in children with sickle cell disease. 2,3 Likewise, glucocorticoid treatment of paroxysmal nocturnal hemoglobinuria (PNH) has been advocated to attenuate the severity of hemolytic crisis by not yet established mechanisms. 4 Glucocorticoid treatment of PNH and sickle cell complications is controversial due to the high incidence of treatment-associated complications and rebound attacks. [4][5][6] Nevertheless, these studies could suggest that glucocorticoids might enhance the level of protection against extracellular hemoglobin (Hb) exposure that occurs during nonimmune intravascular hemolysis in PNH and sickle cell disease. In addition, in autoimmune hemolytic anemia plasma, haptoglobin (Hp) is usually consumed pointing to the leakage of free Hb into the circulation.Extracellular Hb has been associated with toxic adverse effects. 7 Free radicals and...